Enjoy Free Shipping on your First Order

PEPTIDES SOURCE

Search
Close this search box.
Product List

BPC-157

Key Takeaways of BPC 157

  • BPC-157 is a synthetic peptide derived from a protein found in the stomach.
  • It’s often referred to as a “stable gastric pentadecapeptide” due to its stability in human gastric juice.
  • BPC-157 has shown potential benefits in laboratory and preclinical studies, including promoting tissue repair and healing.
  • Potential applications of BPC-157 include wound healing, anti-inflammatory effects, gastrointestinal health, and bone healing.
  • If you are considering using BPC-157, it is important to talk to your doctor first to assess the risks and benefits of this treatment and provide you with guidance on how to use it safely.

Potential Benefits of BPC 157

BPC 157 offers a wide range of therapeutic benefits, including accelerating wound healing and soft tissue injury recovery, improving bone and joint health, enhancing digestive function, and normalizing blood pressure, potassium, calcium, and magnesium levels. It also strengthens the immune system, protects against NSAID-related side effects, reverses alcohol intoxication, and positively impacts mood, behavior, and cognitive health. Additionally, BPC 157 exhibits potential anti-cancer properties, making it a versatile peptide with various health-promoting effects.

  • Accelerates wound healing [1-12]
  • Accelerates healing of soft tissue injuries [13-28]
  • Improves bone and joint health [29-32]
  • Improves digestive health [33-45]
  • Normalizes blood pressure [46-49]
  • Corrects potassium imbalance [50-55]
  • Corrects calcium imbalance [56]
  • Corrects magnesium imbalance [57]
  • Strengthens the immune system [58-63]
  • Protects against NSAID toxicity and related adverse side effects [64-68]
  • Reverses alcohol intoxication [69-72]
  • Improves mood and behavior [73-77]
  • Improves cognitive health [78-82]
  • Exerts anti-cancer properties [83-86]

What is BPC 157?

BPC 157 peptides, also known as Body Protecting Compound 157, Body Protection Compound-157, or BPC-157, consist of a chain of 15 amino acids and originate from human gastric juices. A peptide is simply a compound consisting of two or more amino acids. BPC 157 is commonly known as a “stable gastric pentadecapeptide” because of its ability to maintain stability even within the environment of human gastric juice.

Your body already produces BPC-157 in very small amounts, which serves to signal certain body processes to happen and protect the digestive system. Researchers believe that if you get the super concentrated version of BPC-157 into your system, it has an extremely high level of regenerative effects.

How BPC-157 works?

BPC-157 works by stimulating the formation of new blood vessels. This process is called angiogenesis and is important in promoting healing and faster cell regeneration. Angiogenesis is an integral part of the wound-healing process and the organization of the blood vessel network.

Research on BPC 157 Benefits

A. Speeds Up the Wound Healing Process

Numerous studies show that BPC-157 may help accelerate the wound-healing process through multiple mechanisms:

  1. In mice with burn injuries, BPC-157 was able to treat skin burns by significantly improving collagen fiber formation and decreasing the number of inflammatory cells. [1-4]
  2. In wounded rats, BPC-157 administration enhanced the formation of granulation tissues (new tissues that form on an ulcer or the healing surface of a wound) and new blood vessels. [5-6]
  3. A study found that BPC-157 was able to treat skin burns by enhancing wound healing in a model of alkali burn-induced skin injury. [7]
  4. In rats with intestinal lesions, BPC-157 administration significantly reduced damage to blood vessels and occlusion. [8-9]
  5. In rats with celecoxib-induced gastrointestinal, liver, and brain lesions, BPC-157 reversed the damaging effect of the drug. [10]
  6. In broiler chicks with severe damage to the tissues of the heart, liver, and spleen, BPC-157 administration at 10 micrograms/kg reduced organ damage. [11]
  7. In honeybees with severe damage to midgut wall layers, supplementation with sugar syrup containing BPC-157 decreased damage to the outer muscular coat. [12]

Discover the future of wound healing with innovative peptides. Explore the power of Wound Healing Peptides in accelerating recovery and regeneration. Unleash the potential of cutting-edge research for effective wound healing solutions.

 

B. Accelerates Healing of Soft Tissue Injuries

Soft tissue injuries refer to damage to the muscles, tendons, and ligaments. They can be partial or complete tears and may require surgical repair. Interestingly, BPC-157 has shown promise in preclinical studies for promoting the healing of tendon-to-bone damage, potentially accelerating the recovery process in musculoskeletal injuries:

  1. In rats with Achilles tendon injury, BPC-157 significantly improved healing, thereby eliminating the need for surgical repair. [13-15]
  2. BPC-157 promoted tendon outgrowth, cell survival, and cell migration in the injured soft tissues of rats, resulting in improved soft tissue healing. [16-18]
  3. In rats with muscle crush injury, BPC-157 induced faster muscle healing and full function restoration. [19-21]
  4. In rat tendon cells, pretreatment with BPC-157 showed outcomes close to the noninjured ligament as evidenced by faster granulation tissue formation, better organization of collagen, and reduced inflammatory cells, suggesting improved ligament healing. [22]
  5. In rats that had a surgical operation of the colon, BPC-157 treatment accelerated the healing time. [23]
  6. In rats with eye injuries, administration of BPC-157 eye drops successfully closed perforating corneal incisions. [24-25]
  7. In rats with injury to the sciatic nerve (nerve in the spinal cord), BPC-157 administration reversed the death of nerve cells and cyst formation and protected against damage to nerve structures. [26]
  8. A study also found that BPC-157 has the capacity to protect against cancer cachexia, a condition characterized by progressive loss of muscle and fat. [27]
  9. In rats with vessel injury, BPC-157 administration counteracted direct vein injury, blood clots, and prolonged bleeding. [28]

C. Improves Bone and Joint Health

BPC-157 plays a crucial role in maintaining bone and joint health. Studies show that BPC-157 exerts this beneficial effect through the following:

  1. In rabbits, BPC-157 significantly improved the healing of segmental bone defects by increasing bone density. [29]
  2. In rats, BPC-157 administration counteracted knee osteoarthritis and reduced cartilage lesions and joint pain, resulting in improved leg length and mobility. [30-32]

D. Improves Digestive Health

Current research suggests that BPC-157 may also help improve digestive function and overall digestive health through the following:

  1. In rats, BPC-157 prevented the development of stomach ulcers by protecting the layers of the stomach against the direct cellular damaging effect of ethanol. [33-34]
  2. BPC-157 fully interacted with the dopamine system (group of nerve cells in the midbrain) of rats to prevent mechanisms involved in ulcer formation. [35]
  3. Continuous administration of BPC-157 in rats with chronic gastric ulcers accelerated the rebuilding of stomach tissues and the formation of granulation tissues. [36]
  4. BPC-157 administration in rats was able to treat stomach ulcer by reducing gastrointestinal tract lesions. [37-40]
  5. In rats with inflammatory bowel disease, BPC-157 administration resulted in faster healing of the damaged colon and improved tendon, bone, and ligament healing by boosting the levels of Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), and Vascular Endothelial Growth Factor (VEGF). [41-45]

E. Normalizes Blood Pressure

Studies show that BPC-157 can help normalize blood pressure through the following mechanisms:

  1. In rats with abnormally low blood pressure, BPC-157 exerted hypertensive effects by increasing blood pressure near the normal range. [46-47]
  2. In rats with high blood pressure, BPC-157 decreased blood pressure by causing blood vessels to dilate. [48-49]

F. Corrects Potassium Imbalance

Normal blood levels of potassium are crucial for optimum heart health. Abnormally low or high potassium levels can both lead to heart failure. Studies show that BPC-157 can help protect against heart failure caused by potassium imbalance:

  1. In rats with hyperkalemia (potassium overdose), BPC-157 therapy protects against heart failure by completely restoring the normal heart rhythm and electrical activities of the heart. [50-53]
  2. In rats with hypokalemia (potassium deficiency), BPC-157 therapy protects against heart failure by counteracting abnormal heart rhythm. [54-55]

G. Corrects Calcium Imbalance

Hypercalcemia (excessive calcium levels) negatively affects almost every organ system in the body. Evidence suggests that BPC-157 can counteract life-threatening conditions associated with high calcium levels:

  1. In rats, BPC-157 administration protected against organ failure induced by hypercalcemia via the reduction of calcium deposits. [56]

H. Corrects Magnesium Imbalance

High levels of magnesium in the blood (hypermagnesemia) can lead to life-threatening conditions including heart problems, breathing difficulties, and coma. Evidence found that BPC-157 can help reverse this electrolyte imbalance:

  1. In rats, BPC-157 administration counteracted the initial event leading to hypermagnesemia and the life-threatening effects of magnesium overdose. [57]

I. Strengthens the Immune System

BPC-157 can help boost the immune system and protect against infection caused by viruses, bacteria, and other disease-causing microorganisms through the following important mechanisms:

  1. BPC-157 has been shown to have anti-inflammatory and regenerative effects on multiple target tissues and organs of rats. [58]
  2. In rats, BPC-157 increased the production of growth factors that fight infections such as vascular endothelial growth factors (VEGF), ultimately strengthening the immune system. [59-62]
  3. A cell study found that BPC-157’s inflammation reduction effects on the intestines are exerted through its antioxidant properties. [63]

K. Reverses Alcohol Intoxication

BPC-157 can help reverse the adverse effects of acute and chronic alcohol intoxication. Studies show that BPC-157 exerts this effect through the following:

  1. In mice, BPC-157 rapidly opposed the strongest disturbance presentations in acute alcohol intoxication such as loss of muscle reflex, no reaction to external stimuli, and low body temperature, as well as symptoms of alcohol withdrawal such as prominent seizures. [69]
  2. BPC-157 protected against both acute and chronic alcohol-induced lesions in the stomach, esophagus, and liver of mice. [70-72]

M. Improves Cognitive Health

An overwhelming body of research supports the benefits of BPC-157 on the brain:

  1. In rats with brain damage similar to Parkinson’s disease (PD), administration of BPC-157 appears to mitigate some of the damage. [78]
  2. In rodents with multiple sclerosis (MS), a chronic disease affecting the brain and spinal cord, oral BPC-157 administration decreased brain damage and clinical abnormalities. [79-80]
  3. In rats with traumatic brain injury, BPC-157 administration is associated with a reduction of unconsciousness and a lower prevalence of deaths. [81]
  4. In rats, BPC-157 counteracted ischemic/reperfusion injuries (tissue damage caused when blood supply returns after a period of insufficient blood circulation in the brain), resulting in improved memory, orientation, and motor capabilities. [82]

N. Exerts Anti-Cancer Properties

Therapeutic peptides such as BPC-157 are known to possess potent anti-cancer activity. Most animal studies assessing the therapeutic benefits of BPC-157 have shown that this therapeutic peptide helps fight cancer by:

  1. Inducing programmed cell death (apoptosis) of cancer cells [83-85]
  2. Assembling and forming pores that can disrupt the structures of cancer cells [86]

Boost Cell Health and Recovery with BPC 157 Peptide

The potential to boost cell health and recovery with BPC-157 is an area of ongoing research. While there are indications that BPC-157 may have positive effects on tissue repair and healing processes, its precise mechanisms and overall impact on cell health are not fully understood. Some potential ways in which BPC-157 might contribute to cell health and recovery include:

  • Tissue Repair: BPC-157 has been studied for its ability to stimulate collagen production and angiogenesis, which could aid in the repair of damaged tissues, including muscles, tendons, ligaments, and the gastrointestinal tract.
  • Anti-Inflammatory Effects: BPC-157 may exhibit anti-inflammatory properties, potentially helping to treat inflammatory conditions and support the healing process.
  • Blood Flow and Oxygen Supply: By promoting angiogenesis, BPC-157 might enhance blood vessel formation, leading to improved blood flow and oxygen supply to tissues, which are essential for cell health and recovery.
  • Cellular Protection: Some research suggests that BPC-157 might have antioxidant effects, which could help protect cells from oxidative stress and damage.
  • Wound Healing: BPC-157’s potential to accelerate wound healing might extend to cellular repair processes, contributing to overall tissue regeneration.

BPC 157 Side Effects

BPC-157 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on BPC-157. However, the issue wasn’t’ confirmed to be caused by the treatment and could have been a coincidence and not related to the use of BPC-157. Despite this, it was listed as a side effect associated with BPC-157 even though these associated side effects are very uncommon.

Side effects associated with BPC-157 may include the following:

  • Changes in blood pressure
  • Changes in heart rhythm
  • Dizziness
  • Fatigue
  • Hot flashes
  • Nausea and vomiting

BPC 157 Dosage

The dosage of BPC-157 can vary depending on the individual and the condition being treated. In general, the prescriptions are based on body weight. However, a typical dosage range is 200-800 micrograms (mcg) per day. This can be taken as a single dose or divided into two or more doses.

For intramuscular injection of BPC-157, the dose is typically 16 units (16 mcg) per dose, twice a day. The injections can be given subcutaneously (under the skin) or intramuscularly (into the muscle).

For oral administration of BPC-157, the dose is typically 500 mcg per dose, twice a day. The capsules can be taken with or without food.weight

It is important to start with a low dose of BPC-157 and gradually increase it as tolerated. Some people may experience side effects such as nausea, headache, or fatigue at higher doses.

If you are considering using BPC-157, it is important to talk to your doctor first. They can help you assess the risks and benefits of this supplement and make sure that it is right for you.

Here are some additional dosage guidelines for BPC-157:

  • For the treatment of acute injuries, a higher dose may be necessary.
  • For the treatment of chronic conditions, a lower dose may be sufficient.
  • The dosage may need to be adjusted depending on the individual’s response.

BPC 157 Before and After Results

About Dr. George Shanlikian

Dr. George Shanlikian, renowned as the world’s best hormone therapy doctor, possesses expertise in various medical domains. These include Bio-Identical Hormone Replacement Therapy, Peptide Replacement Therapy, Anti-Aging Medicine, Regenerative Medicine, Stress Management, Nutrition Consulting, Nutritional Supplement Consulting, and Exercise Consulting.

References

  1. Mikus D, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns: journal of the International Society for Burn Injuries. 2001; 27(8):817-27.
  2. Bilic M., Bumber Z., Blagaic A.B., Batelja L., Seiwerth S., Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns. 2005;31(3):310–315.
  3. Sikiric P., Seiwerth S., Mise S., Staresinic M., Bedekovic V., Zarkovic N., Borovic S., Gjurasin M., Boban-Blagaic A., Batelja L., Rucman R., Anic T. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns. 2003;29(4):323–334.
  4. Mikus D, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns: journal of the International Society for Burn Injuries. 2001; 27(8):817-27.
  5. Seiwerth S, Sikiric P, Grabarevic Z. BPC 157’s effect on healing. Journal of physiology, Paris. ; 91(3-5):173-8.
  6. Seveljević-Jaran D, Cuzić S, Dominis-Kramarić M. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin pharmacology and physiology. 2006; 19(5):266-74.
  7. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485–2499. doi: 10.2147/DDDT.S82030.
  8. Drmic D, Samara M, Vidovic T, et al. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018;24(48):5462-5476.
  9. Amic F, Drmic D, Bilic Z, et al. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018;24(47):5366-5378.
  10. Drmic D, Kolenc D, Ilic S, et al. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World J Gastroenterol. 2017;23(29):5304-5312.
  11. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol Paris. 1997;91(3-5):139-49.
  12. TlakGajger I, Ribarić J, SmodišŠkerl M, Vlainić J, Sikirić P. Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions. J Vet PharmacolTher. 2018;41(4):614-621. doi:10.1111/jvp.12509.
  13. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of orthopaedicresearch : official publication of the Orthopaedic Research Society. 2006; 24(5):982-9.
  14. Staresinic M., Sebecic B., Patrlj L., Jadrijevic S., Suknaic S., Perovic D., Aralica G., Zarkovic N., Borovic S., Srdjak M., et al. Gastric pentadecapeptide BPC 157 accelerated healing of transected rat Achilles tendon and in vitro stimulates tenocytes growth. J. Orhtop. Res. 2003;21:976–983. doi: 10.1016/S0736-0266(03)00110-4.
  15. Molloy T.J., Wang Y., Horner A., Skerry T.M., Murrell G.A. Microarray analysis of healing rat Achilles tendon: Evidence for glutamate signaling mechanisms and embryonic gene expression in healing tendon tissue. J. Orthop. Res. 2006;24:842–855. doi: 10.1002/jor.20093.
  16. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011; 110(3):774-80.
  17. Staresinic M, Sebecic B, Patrlj L. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2003; 21(6):976-83.
  18. Gjurasin M, Miklic P, Zupancic B. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory peptides. 2010; 160(1-3):33-41.
  19. Pevec D, Novinscak T, Brcic L. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical science monitor : international medical journal of experimental and clinical research. 2010; 16(3):BR81-88.
  20. Novinscak T, Brcic L, Staresinic M. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery today. 2008; 38(8):716-25.
  21. Novinscak T, Brcic L, Staresinic M. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery today. 2008; 38(8):716-25.
  22. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. Published 2014 Nov 19. doi:10.3390/molecules191119066.
  23. Zoricic I., Sikiric P., Seiwerth S. Pentadecapeptide BPC-157 beneficially influences the healing of colon-colon anastamoses in rats. In: Mozsik G., Nagy L., Par A., Rainsford K., editors. Cell Injury and Protection in the Gastrointestinal Tract. From Basic Science to Clinical Perspectives. Kluwer Academic Publishers; Dodrecht, The Netherlands: 1997. pp. 249–258.
  24. Konjevoda P., Nasic M., Curkovic T. Effects of BPC-157 on the healing of corneal lesions. In: Ohno S., Aoki K., Usui M., editors. Uveitis Today. Elsevier; Amsterdam, The Netherlands: 1998. pp. 311–314.
  25. Masnec S, Kokot A, Zlatar M, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015;136:9-15.
  26. Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019;14(1):199. Published 2019 Jul 2. doi:10.1186/s13018-019-1242-6.
  27. Kang EA, Han YM, An JM, Park YJ, Sikiric P, Kim DH, et al. BPC157 as potential agent rescuing from cancer cachexia. Curr Pharm Des. 2018;24(18):1947–1956. doi: 10.2174/1381612824666180614082950.
  28. Vukojević J, Siroglavić M, Kašnik K, et al. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. VasculPharmacol. 2018;106:54-66. doi:10.1016/j.vph.2018.02.010.
  29. Sebecić B, Nikolić V, Sikirić P. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999; 24(3):195-202.
  30. Retrieved from http://www.fasebj.org/content/28/1_Supplement/844.11?related-urls=yes&legid=fasebj;28/1_Supplement/844.11.
  31. Retrieved from https://www.dovepress.com/role-of-nutrients-in-metabolic-syndrome-a-2017-update-peer-reviewed-fulltext-article-NDS.
  32. Retrieved from https://www.sciencedirect.com/science/article/pii/S0928425797894740.
  33. Bódis B, Karádi O, Németh P, Dohoczky C, Kolega M, Mózsik G. Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life sciences. 1997; 61(16):PL 243-8.
  34. Prkacin I., Aralica G., Perovic D., Separovic J., Gjurasin M., Lovric-Bencic M., Stancic-Rokotov D., Ziger T., Anic T., Sikiric P., et al. Chronic cytoprotection: Pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J. Physiol. Paris. 2001;95:295–301. doi: 10.1016/S0928-4257(01)00041-9.
  35. Jelovac N, Sikiric P, Rucman R. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. European journal of pharmacology. 1999; 379(1):19-31.
  36. Xue XC, Wu YJ, Gao MT. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World journal of gastroenterology. 2004; 10(7):1032-6.
  37. Stancic-Rokotov D, Slobodnjak Z, Aralica J. Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. Journal of physiology, Paris. ; 95(1-6):303-8.
  38. Sikiric P, Seiwerth S, Grabarevic Z. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life sciences. 1994; 54(5):PL63-8.
  39. Djakovic Z, Djakovic I, Cesarec V, et al. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World Journal of Gastroenterology. 2016;22(41):9127-9140. doi:10.3748/wjg.v22.i41.9127.
  40. Klicek R., Sever M., Radic B., Drmic D., Kocman I., Zoricic I., Vuksic T., Ivica M., Barisic I., Ilic S., et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: Role of the nitric oxide-system. J. Pharmacol. Sci. 2008;108:7–17. doi: 10.1254/jphs.FP0072161./PMC5107594/.
  41. Sikiric P., Petek M., Rucman R., Seiwerth S., Grabarević Z., Rotkvić I., Jagić V., Turković B., Mildner B., Duvnjak M., et al. The significance of the gastroprotective effect of body protection compound (BPC): Modulation by different procedures. Acta Physiol. Hung. 1992;80:89–98.
  42. Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989. doi: 10.2174/1381612824666180712110447.
  43. Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990–2001. doi: 10.2174/1381612824666180608101119.
  44. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126–132. doi: 10.2174/092986712803414015.
  45. Duzel A, Vlainic J, Antunovic M, Malekinusic D, Vrdoljak B, Samara M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017;23(48):8465–8488. doi: 10.3748/wjg.v23.i48.8465.
  46. Sikirić P, Seiwerth S, Grabarević Z. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European journal of pharmacology. 1997; 332(1):23-33.
  47. Sikiric P, Seiwerth S, Rucman R. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? Current pharmaceutical design. 2017; 23(27):4012-4028.
  48. Sikiric P, Seiwerth S, Rucman R. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current pharmaceutical design. 2014; 20(7):1126-35.
  49. Prkacin I, Separovic J, Aralicia G. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. Journal of physiology, Paris. ; 95(1-6):315-24.
  50. Barisic I, Balenovic D, Klicek R. Mortal hyperkalemia disturbances in rats are NO-system related. The life-saving effect of pentadecapeptide BPC 157. Regulatory peptides. 2013; 181:50-66.
  51. Stambolija V, Stambolija TP, Holjevac JK. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. European journal of pharmacology. 2016; 781:83-91.
  52. Available from https://www.croris.hr/crosbi/publikacija/prilog-skup/562833.
  53. Zivanovic-Posilovic G, Balenovic D, Barisic I. Stable gastric pentadecapeptide BPC 157 and bupivacaine. European journal of pharmacology. 2016; 793:56-65.
  54. Strinic D, Belosic Halle Z, Luetic K. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life sciences. 2017; 186:66-79.
  55. Retrieved from https://www.omicsonline.org/mortal-furosemide-hypokalemia-disturbances-in-rats-no-system-related-shorten-survival-by-l-name.-therapy-benefit-with-bpc-157-peptide-morethan-with-l-arginine-2155-9880.1000201.php?aid=6879.
  56. Ilic S, Brcic I, Mester M. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:107-14.
  57. Medvidovic-Grubisic M, Stambolija V, Kolenc D. Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen. Inflammopharmacology. 2017; 25(4):439-449.
  58. Keremi B, Lohinai Z, Komora P. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:115-22.
  59. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2009; 60 Suppl 7:191-6.
  60. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug testing and analysis. 2017; 9(10):1490-1498.
  61. Sikiric P, Seiwerth S, Rucman R. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current neuropharmacology. 2016; 14(8):857-865.
  62. Hsieh MJ, Liu HT, Wang CN. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany). 2017; 95(3):323-333.
  63. Škrlec K, Ručman R, Jarc E, et al. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol. 2018;102(23):10103-10117. doi:10.1007/s00253-018-9333-6.
  64. Sikiric P, Seiwerth S, Rucman R. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current pharmaceutical design. 2013; 19(1):76-83.
  65. Ilic S, Drmic D, Franjic S. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life sciences. 2011; 88(11-12):535-42.
  66. Vitaic S, Stupnisek M, Drmic D. Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatricpentadecapeptide BPC 157 in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2017; 68(2):265-272.
  67. Sikiric P, Seiwerth S, Rucman R. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current pharmaceutical design. 2011; 17(16):1612-32.
  68. Ilic S, Drmic D, Zarkovic K. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. European journal of pharmacology. 2011; 667(1-3):322-9.
  69. Boban-Blagaic A, Blagaic V, Romic Z. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Medical science monitor : international medical journal of experimental and clinical research. 2006; 12(1):BR36-45.
  70. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. European journal of pharmacology. 2004; 499(3):285-90.
  71. Sikiric P, Seiwerth S, Brcic L. Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Current pharmaceutical design. 2010; 16(10):1224-34.
  72. Sikiric P, Seiwerth S, Brcic L. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006; 14(5-6):214-21.
  73. Sikiric P, Separovic J, Buljat G. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats. A comparison with antidepressants. Journal of physiology, Paris. ; 94(2):99-104.
  74. Sikiric P, Jelovac N, Jelovac-Gjeldum A. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. ActapharmacologicaSinica. 2001; 22(3):225-30.
  75. Sikiric P, Jelovac N, Jelovac-Gjeldum A. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. ActapharmacologicaSinica. 2002; 23(5):412-22.
  76. BobanBlagaic A, Blagaic V, Mirt M. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. European journal of pharmacology. 2005; 512(2-3):173-9.
  77. Jelovac N, Sikiric P, Rucman R. The effect of a novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated administration of diazepam. The Chinese journal of physiology. 1999; 42(3):171-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10707891.
  78. Sikiric P, Marovic A, Matoz W. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. Journal of physiology, Paris. 1999; 93(6):505-12.
  79. Klicek R, Kolenc D, Suran J. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2013; 64(5):597-612.
  80. Torkildsen O, Brunborg LA, Myhr KM, Bø L. The cuprizone model for demyelination. ActaneurologicaScandinavica. Supplementum. 2008; 188:72-6.
  81. Tudor M, Jandric I, Marovic A. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory peptides. 2010; 160(1-3):26-32.
  82. Retrieved from http://www.fasebj.org/content/30/1_Supplement/706.5.short.
  83. Yu-Feng Xiao, Meng-MengJie, Bo-Sheng Li, et al., “Peptide-Based Treatment: A Promising Cancer Therapy,” Journal of Immunology Research, vol. 2015, Article ID 761820, 13 pages, 2015. doi:10.1155/2015/761820.
  84. Cerezo D, Peña MJ, Mijares M, Martínez G, Blanca I, De Sanctis JB. Peptide vaccines for cancer therapy. Recent patents on inflammation & allergy drug discovery. 2015; 9(1):38-45.
  85. Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer-old concept revisited. Current opinion in immunology. 2017; 45:1-7.
  86. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The Use of Therapeutic Peptides to Target and to Kill Cancer Cells. Current medicinal chemistry. 2012;19(22):3794-3804.
Shopping Cart

Product Index :

Alcohol and Drug Withdrawal:

Epithalon

DSIP

Anti-Aging & Longevity:

5-amino-1mq

Glutathione

AICAR

Epithalon

MOTS-C

FOXO4-DRI (Proxofim)

Blood Sugar Control:

Semaglutide (Tablets)

Adipotide

AICAR

Tirzepatide

Semaglutide

Brain, CNS and Nerves:

Oxytocin Acetate

Semax

Selank

Focus and Energy:

5-amino-1mq

SS-31

GHK-CU

Gut and Digestion:

BPC-157 (Tablets)

BPC 5mg + TB 5mg

BPC-157

LL-37

Immune Regulation:

Thymosin Alpha-1

AICAR

Injury Healing and Recovery:

BPC-157 (Tablets)

BPC 5mg + TB 5mg

TB500 Thymosin B4 Acetate

BPC-157

Muscle and Strength:

Cabergoline/Dostinex

17a-Methyl-1-testosterone M1T

Hexarelin Acetate

IGF-DES

IGF-1LR3

GDF-8

Muscle Growth:

Test

Flibanserin

Finasteride

Cabergoline/Dostinex

17a-Methyl-1-testosterone M1T

Semaglutide (Tablets)

Pain and Inflammation:

BPC-157 (Tablets)

Thymalin

BPC 5mg + TB 5mg

AICAR

BPC-157

DSIP

Sexual Wellness:

Flibanserin

Triptorelin/Acetate/GnRH

Gonadorelin Acetate

PT-141

Follistatin

KissPeptin-10

Skin:

MT-2 (Melanotan 2 Acetate)

Sleep:

Melatonin

DSIP

MT-2 (Melanotan 2 Acetate)

Weight Management:

Cabergoline/Dostinex

Semaglutide (Tablets)

TB500 Tesofensine

5-amino-1mq

GLP-1

CJC-1295 Without DAC 5mg + Ipomorelin 5mg